Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Vitrolife

Vitrolife

Read in Swedish

Vitrolife AB (publ): Interim report January - September 2020: Good profitability and continued recovery

08:00 / 6 November 2020 Vitrolife Press release

Third quarter:
  • Sales amounted to SEK 320 (378) million, corresponding to a decrease of 15 percent in SEK. Sales decreased by 11 percent in local currency. Sales were negatively impacted by Covid-19 as a result of reduced demand. During the third quarter the recovery in demand continued, even though the rate of recovery varied between divisions and market regions.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 134 (155) million, corresponding to a margin of 42 (41) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 9 million.
  • Net income amounted to SEK 89 (107) million, which gave earnings per share of SEK 0.81 (0.98).
January - September:
  • Sales amounted to SEK 863 (1 071) million, corresponding to a decrease of 19 percent in SEK. Sales decreased by 19 percent in local currency. Sales were negatively impacted by Covid-19 as a result of reduced demand.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 290 (428) million, corresponding to a margin of 34 (40) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 3 million.
  • Net income amounted to SEK 180 (287) million, which gave earnings per share of SEK 1.65 (2.64).

Gothenburg, November 6, 2020
VITROLIFE AB (publ)
Thomas Axelsson, CEO

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com.Website: www.vitrolife.com/

Show as PDF

Show original from Cision

Cision

This information was distributed by Cision http://www.cisionwire.se/